ArticleBritish journal of haematology2022
International guidelines regarding the role of IVIG in the management of Rh- and ABO-mediated haemolytic disease of the newborn.
Article in British journal of haematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 26 citations in OpenAlex.
- Efficacy of intravenous immunoglobulin following plasma exchange in the management of ABO haemolytic disease of the newborn.Vox sanguinis · 2026Trial
- Urinary carbonic anhydrase 1 excretion is a marker of hemolysis-triggering conditions suitable for point-of-care testing.Blood global hematology · 2026Article
- The timing of using IVIG for neonatal ABO hemolytic disease.BMC pediatrics · 2025Article
- How do we leverage implementation science to support and accelerate uptake of clinical practice guidelines in transfusion medicine.Transfusion · 2025Article
- Variations and Opportunities in Postnatal Management of Hemolytic Disease of the Fetus and Newborn.JAMA network open · 2025Observational
- Effect of intravenous immunoglobulin on the management of Rh- and ABO-mediated hemolytic disease of the newborn.Hematology, transfusion and cell therapy · 2024Article
- Severe Hemolytic Disease of the Newborn due to Anti-DiJournal of medical cases · 2023Article
- Clinical value of combined predictors of RET%, γ-GT, LDH in the ABO neonatal hemolytic disease.Frontiers in pediatrics · 2023Article
- [Interpretation of "International guidelines regarding the role of IVIG in the management of Rh- and ABO-mediated haemolytic disease of the newborn"].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2022Article
- International guidelines regarding the role of IVIG in the management of Rh- and ABO-mediated haemolytic disease of the newborn.British journal of haematology · 2022Article
- Irregular antibodies in pregnancy during the universal anti-RHD prophylaxis era: a survey of Spanish Hospitals.Blood transfusion = Trasfusione del sangueReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 19 institutions in 10 countries.
Funding
Abstract
Haemolytic disease of the newborn (HDN) can be associated with significant morbidity. Prompt treatment with intensive phototherapy (PT) and exchange transfusions (ETs) can dramatically improve outcomes. ET is invasive and associated with risks. Intravenous immunoglobulin (IVIG) may be an alternative therapy to prevent use of ET. An international panel of experts was convened to develop evidence-based recommendations regarding the effectiveness and safety of IVIG to reduce the need for ETs, improve neurocognitive outcomes, reduce bilirubin level, reduce the frequency of red blood cell (RBC) transfusions and severity of anaemia, and/or reduce duration of hospitalization for neonates with Rh or ABO-mediated HDN. We used a systematic approach to search and review the literature and then develop recommendations from published data. These recommendations conclude that IVIG should not be routinely used to treat Rh or ABO antibody-mediated HDN. In situations where hyperbilirubinaemia is severe (and ET is imminent), or when ET is not readily available, the role of IVIG is unclear. High-quality studies are urgently needed to assess the optimal use of IVIG in patients with HDN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.